Skip to main content
LIVN logo

LIVN · LivaNova PLC

Track LIVN — free
$92.64 +0.20 (+0.22%)
Market Cap
$5.09B
Shares
55.09M
Volume · Nov 17 87.86K Avg daily vol (3M) 670.55K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$92.44 Open$90.77 Day$90.76–94.86 52W close$53.42–94.19 Avg vol 30d718K Short int6.4M · 11.5% of shares · 12.4d Short vol63% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 10
Investor event
2027 sleep apnea launch planned

LivaNova plans a 2027 obstructive sleep apnea launch after submitting a PMA supplement between the end of this year and first half of next year; management expects OSA margin north of 25% by 2030.

4 source passages
So, yes, we are very confident that the LMR will happen in 2027. Between the end of this year and first half of next year, we will submit the PMA supplement. And so we expect by 2030, OSA margin itself will be north of 25%. any neuromodulation implant from Livanova would be able to be upgraded with this new device when they have their replacement. Open the document at this passage
Nov 9
Investor event
Guidance raised; OSA target $200 million to $400 million

LivaNova raised revenue guidance by 100 bits and EPS guidance by 10 cents, citing stronger cardiopulmonary and epilepsy execution. It reiterated its $200 million to $400 million OSA revenue target by 2030.

2 source passages
we raised guidance about 100 bits, just to be crystal clear on that front, from a top-line perspective, and increased our EPS guide by about 10 cents. we kind of reiterated our commitment to that $200 million to $400 million revenue target that we put out for our OSA business by 2030. Open the document at this passage
Nov 4
Earnings call
Revenue growth rises as 2026 guidance strengthens

LivaNova reported third-quarter revenue of $393 million, up 10%, and raised 2026 revenue growth guidance to 9% to 10% from 8% to 9%, while lifting adjusted diluted EPS guidance to $4.40 to $4.50.

4 source passages
LivaNova's innovation engine continues to drive growth today, while building the foundation for sustained long-term value creation. third quarter revenue was $393 million, an increase of 10% versus the prior year. We now forecast 2026 revenue growth between 9% and 10% on a constant currency basis, up from 8% to 9% previously. And now project adjusted diluted earnings per share in the range of $4.40 to $4.50. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA approved aura6000 for moderate to severe OSA

LivaNova PLC said the FDA granted PMA on March 18, 2026, for the aura6000 System to treat adult patients with moderate to severe OSA who failed, do not tolerate, or are ineligible for first-line therapies.

Revenue $393.15M ▲ 9.9% Net income $34.29M ▲ 28.0% Diluted EPS $0.11 ▼ 77.6%
Read from the MD&A section
Source passage
On March 18, 2026, the FDA granted PMA for the aura6000 System for the treatment of adult patients with moderate to severe OSA who have failed, do not tolerate, or are ineligible for first-line therapies, such as positive airway pressure. Open the document at this passage
Nov 4
Current report 8-K
LivaNova raises 2026 revenue and EPS guidance

LivaNova reported third-quarter 2026 revenue of $393.1 million, up 9.9%, and adjusted diluted EPS of $1.23, while raising full-year revenue growth guidance to 9%–10% and adjusted diluted EPS to $4.40–$4.50; adjusted free cash flow guidance remained $140 million–$160 million.

Financial results
3 source passages
•Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period •Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per share of $1.23 •Raised full-year 2026 revenue growth range by 100 basis points to 9% to 10% on a constant-currency basis. Raised full-year 2026 adjusted diluted earnings per share range by $0.10 at midpoint to $4.40 to $4.50. Maintained full-year 2026 adjusted free cash flow range of $140 million to $160 million Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.51B
Trailing 12 months
Net income (TTM)
$196.06M
Trailing 12 months
Revenue growth YoY
+9.9%
Year over year
Operating margin
10.7%
Trailing 12 months
P / E (TTM)
30.3
Trailing earnings · reciprocal yield 3.3%
FCF yield
2.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$264.38M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.0%
Year over year · more shares
Price change (1Y)
+67.0%
Trailing year
Short interest
11.5%
Latest settlement · 12.4 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. LivaNova delivered Q2 2026 revenue of $390.6 million (up 9.8% constant-currency / 10.8% reported) with record adjusted EPS of $1.26, raised full-year 2026 revenue growth outlook to 8%–9% and adjusted EPS to $4.30–$4.40, but lowered adjusted free-cash-flow guidance to $140–$160 million due to higher capex and Thermo Fisher funding.

Bullish
  • + Full-year 2026 revenue guidance raised to 8%–9% (from 7%–8%) constant-currency
  • + Cardiopulmonary segment outlook raised to 9.5%–10.5% growth (from 8.5%–9.5%)
  • + Epilepsy segment outlook raised to 7%–8% growth (from 6%–7%) on reimbursement and CORE data
Bearish
  • − Full-year 2026 adjusted free-cash-flow guidance lowered to $140–$160 million (from $160–$180 million)
  • − Full-year capex raised to $135 million (from $120 million) for capacity expansion and IT
  • − OSA PMA supplement timing pushed to between 2H 2026 and 1H 2027 from prior 2H 2026 expectation
  • − Adjusted free cash flow of $45.5 million declined modestly YoY on higher capex and working capital

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg +15%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 96%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +18%
trailing
6-month return +25%
trailing
YTD return +50%
this year
Relative strength +26%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $81 › 200d $74 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +45 funds added
Insider flow Distributing
Net -$591.8K over 90 days · 100% sells
Short interest Rising
11.55% of shares out · ▲ +2.6% MoM · 12.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
321 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Excellent
Revenue growth +11%
Y/Y
Gross margin 68%
contracting
EPS growth −484%
Y/Y
Free cash flow $173.3M
Buyback $150.0M
authorized
Balance sheet $258.9M
net cash
Quant / Vol
risk profile
Moderate
Volatility 39%
annualized · 1-yr
Max drawdown −19%
past year
ATR 3.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 5, 2026
full year 2026
Cardiopulmonary revenue growth 9.5% – 10.5%
Epilepsy revenue growth 7% – 8%
Revenue growth Raised 8% – 9%
Feb 25, 2026 6% – 7% changed to Aug 5, 2026 8% – 9%
Adjusted operating income margin Non-GAAP Maintained 20% – 21%
May 6, 2026 20% – 21% changed to Aug 5, 2026 20% – 21%
Adjusted diluted earnings per share Non-GAAP Raised $4.30 – $4.40
Feb 25, 2026 $4.15 – $4.25 changed to Aug 5, 2026 $4.30 – $4.40
Capital spending Raised $135M
May 6, 2026 $120M changed to Aug 5, 2026 $135M
Adjusted effective tax rate Non-GAAP Maintained 23%
May 6, 2026 23% changed to Aug 5, 2026 23%
Adjusted free cash flow Non-GAAP Lowered $140M – $160M
May 6, 2026 $160M – $180M changed to Aug 5, 2026 $140M – $160M
2030
OSA revenue target $200M – $400M
Previous outlook earlier release · from the Earnings Call filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

Cardiopulmonary revenue · full year 2026 8.5% – 9.5%
Epilepsy revenue · full year 2026 6% – 7%
Revenue growth on a constant currency basis · full year 2026 7% – 8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
+15% Bullish
RSI (14)
67 Neutral
MACD trend
Positive Bullish
52-week position
96% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $81 › 200d $74 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +45 funds added
Insider flow Distributing
Net -$591.8K over 90 days · 100% sells
Short interest Rising
11.55% of shares out · ▲ +2.6% MoM · 12.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
321 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $53 Now $92 · 96% Range high $94
vs 200-day avg +24% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted free cash flow non-GAAP $45.5M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities $66.6M
-$31.6M Purchases of property, plant, and equipment
-$0.2M Dividends received from investments
+$10M Payment of contingent consideration included in cash provided by operating activities
+$0.7M 3T Heater-Cooler litigation payments
= Adjusted free cash flow $45.5M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LIVN
LivaNova PLC
this stock
$5.09B +50.2% +10.7% — 11.5%
ABT
Abbott Laboratories
$186.10B -14.2% +5.7% 40.1 1.1%
MDT
Medtronic plc
$131.60B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$118.29B -11.6% +11.2% 33.1 1.7%
BSX
Boston Scientific Corp
$63.33B -54.2% +12.5% 18.5 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
321
% held
110.0%
Net QoQ
+1.2M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
149
View
Short & Settlement
Short Interest Rising
Shares short
6.4M
Days to cover
12.4d
Change
+162.8K sh
View
Short Volume
Short vol %
63%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
741
Value
$59.9K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
45.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$591.8K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$1.4B
Net income (FY)
$-242.5M
EPS diluted
$-4.45
View
Buybacks
Authorized
$150.0M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
19

LivaNova plans a 2027 obstructive sleep apnea launch after submitting a PMA supplement between the end of this year and first half of next year; management expects OSA margin north of 25% by 2030.

View
Proposed Sales
Value
$227.3K
Shares
2.5K
Filed
Nov 12, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
LivaNova Reports Third-Quarter 20…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
LIVN -0.2% +18.3% +25.1% +17.1% +50.2%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY +1.5% +21.8% +26.5% +19.2% +41.7%

Capital returns

Buyback program · as of Nov 15, 2016
Authorized
$150.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1639691 CUSIP G5509L101 13F (30d) 321 filings 299 filers Visit website Investor relations